CORCEPT THERAPEUTICS INC
For the period ended Dec 31, 2025. Filed Feb 24, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Feb 24, 2026
CORT$73.35-2.2%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Income
| Year Ended December 31, | |||
|---|---|---|---|
| 2025 | 2024 | 2023 | |
| Product revenue, net | $761,407 | $675,040 | $482,375 |
| Operating expenses: | |||
| Cost of sales | 12,977 | 10,882 | 6,481 |
| Research and development | 254,908 | 246,887 | 184,353 |
| Selling, general and administrative | 448,725 | 280,320 | 184,259 |
| Total operating expenses | 716,610 | 538,089 | 375,093 |
| Income from operations | 44,797 | 136,951 | 107,282 |
| Interest and other income | 21,666 | 24,542 | 17,275 |
| Income before income taxes | 66,463 | 161,493 | 124,557 |
| Income tax benefit (expense) | 33,189 | (20,284) | (18,417) |
| Net income | $99,652 | $141,209 | $106,140 |
| Net income attributable to common stockholders | $98,171 | $139,733 | $105,496 |
| Basic net income per common share | $0.95 | $1.35 | $1.02 |
| Diluted net income per common share | $0.82 | $1.23 | $0.94 |
| Weighted-average shares outstanding used in computing net income per common share | |||
| Basic | 103,862 | 103,232 | 103,560 |
| Diluted | 119,987 | 113,480 | 111,742 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.